DV
Dividend Vision

ARTV — Artiva Biotherapeutics, Inc. Common Stock

Artiva Biotherapeutics, Inc. Common Stock (ARTV)

Total return is -4.6% over the past 2.1 years, 49.4 points behind SPY at 44.8%. Its deepest 1-year drawdown was 49.2%.

Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers, with lead candidate AlloNK and additional programs targeting solid tumors and hematological malignancies. The company does not currently distribute dividends. Artiva appeals primarily to growth-oriented investors willing to accept the risks associated with early-stage biotechnology development, as the company has no approved products and remains pre-commercial.

ARTV key facts

Asset type
Stock
Asset class
Equity
Inception date
07/19/2024
Last close
$11.45
Market cap
$474,220,832
Average volume
264416.0
Beta
2.177
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.55